Sleep Apnea Syndromes
Conditions
Keywords
intermittent hypoxia, ventilatory long-term facilitation, autonomic nervous system plasticity
Brief summary
The prevalence of obstructive sleep apnea is high in the Veteran population. If not treated promptly, sleep apnea may result in daytime fatigue which may lead to increased prevalence of accidents while driving or in the workplace. Recent large scale epidemiological studies have shown that the prevalence of excessive daytime sleepiness increases in individuals who suffer from obstructive sleep apnea. Obstructive sleep apnea may also result in the development of hypertension and other cardiovascular disorders. Previous findings have shown that subjects with sleep apnea have a greater risk for developing coronary vascular disease compared to individuals that do not suffer from sleep apnea Thus, a significant amount of evidence suggests that sleep apnea is a major health concern in the Veteran population. Consequently, determining the mechanisms that may impact on the severity of sleep apnea and increase the prevalence of cardiovascular incidents associated with this disorder is important, as is discovering novel treatments.
Detailed description
Approximately 8 % of the Veteran population in the United States suffers from sleep apnea. Consequences of untreated sleep apnea include increased daytime fatigue, hypertension and stroke. Thus, sleep apnea is a major health concern. One of the primary hallmarks of sleep apnea is exposure to intermittent hypoxia (IH) which occurs as a consequence of central or obstructive apneas. Exposure to IH may lead to neural plasticity (i.e. a change in system performance based on prior experience) of the respiratory and autonomic nervous system. One adaptation that has been shown to manifest itself in animals following exposure to IH is long-term facilitation (LTF) of ventilation and sympathetic nervous system activity (SNSA). This phenomenon is characterized by a gradual increase in respiratory motor activity and SNSA during successive periods of normoxia that separate hypoxic episodes and by activity that persists above baseline levels for up to 90 minutes following exposure to IH. Although LTF of minute ventilation has been well established in animals it has not been observed consistently in healthy humans or in individuals with obstructive sleep apnea. Similarly, although a few studies have shown that exposure to IH leads to increases in SNSA in healthy individuals the magnitude of the response has varied significantly. Findings from animal studies suggest that the manifestation of LTF in humans might in part be dependent on a variety of factors, including prior exposure to IH, arousal state (wake vs. sleep) and gender. Thus, the initial aim of our proposal will establish whether LTF can be induced in healthy humans and individuals with obstructive sleep apnea and whether the magnitude of the response is dependent on those factors mentioned above. Moreover, the initial aim will explore whether the presence of LTF of minute ventilation promotes or mitigates apnea severity. Animal studies have also indicated that LTF of respiratory and autonomic activity may in part be induced by increases in oxidative stress. Thus, the second objective of our proposal will explore whether administration of an antioxidant cocktail impacts respiratory and autonomic nervous system plasticity during wakefulness and sleep following IH. Likewise, the second aim will explore whether administration of an antioxidant cocktail alters apnea severity following exposure to IH. Establishing whether LTF of minute ventilation exists in individuals with sleep apnea is important since activation of this phenomenon could impact on apnea severity across the night. Similarly, LTF of SNSA activity and possibly long-term depression (LTD) of parasympathetic nervous system activity (PNSA) could ultimately lead to persistent increases in blood pressure and heart rate. Furthermore, given that exposure to IH may lead to long-term plasticity of respiratory and autonomic activity that are physiologically detrimental, exploring mechanisms that ultimately lead to treatments that may mitigate or prevent the manifestation of this phenomenon are important.
Interventions
120 mg of Coenzyme Q10 (orally), 800 mg of Superoxide Dismutase (orally), 400 IU of Vitamin E (orally) before exposure to intermittent hypoxia. Two doses of 1 g of Vitamin C in 50 cc of saline IV (in the vein) before and after exposure to intermittent hypoxia.
Sponsors
Study design
Eligibility
Inclusion criteria
Characteristics of OSA subject population: * Body mass index \< 30 kg/m2. * 20 to 40 years old. * Newly diagnosed never-treated mild to moderate sleep apnea (i.e. 50 \> apnea/hypopnea index \>10 events per hour - average nocturnal oxygen saturation \> 90%). * Not pregnant. * Free of any other known medical conditions. * Not taking any medication. * Non-smokers with normal lung function. * Minimal alcohol consumption (i.e. no more than the equivalent of a glass of wine/day). Characteristics of control group population: * Body mass index \< 30 kg/m2. * 20 to 40 years old. * Apnea/hypopnea index \< 5 events per hour. * Not pregnant. * Free of any known medical conditions. * Not taking any medication. * Non-smokers with normal lung function. * Minimal alcohol consumption (i.e. no more than the equivalent of a glass of wine/day).
Exclusion criteria
* Anything not in inclusion criteria.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Ventilation (Aim 1) | Within the same experimental session | Ventilation was measured before and after exposure to intermittent hypoxia in males and females. Ventilation was measured using a pneumotachograph, which is a flow measuring device. |
| Heart Rate Variability (Aim 2) | Within the same experimental session | Heart rate variability (HRV) was measured before and after exposure to intermittent hypoxia following administration of a placebo or antioxidant cocktail. Heart rate variability refers to beat-to-beat alterations in heart rate. Under resting conditions, the electrocardiogram of healthy individuals reveals periodic variation in R-R intervals. To measure HRV, R-R interval data are presented in a graph, in which the y-axis plots the R-R intervals (ms2), and the x-axis the total number of beats. Spectral analysis of the graph transforms the signal from time to frequency on the x-axis (Hz), by representing the signal as a combination of sine and cosine waves, with different amplitudes and frequencies. The approach uses Fourier transforms. The heart rate spectrum contains a high frequency (0.15-0.4 Hz) component, which is synchronous with respiration and a low frequency (0.04 to 0.15 Hz) component that appears to be mediated by both the vagus and cardiac sympathetic nerves. |
Countries
United States
Participant flow
Recruitment details
This study recruited participants between the years 2009-2013. The study was completed at the John D. Dingell VA Medical Center.
Pre-assignment details
1. Participants did not meet the inclusion criteria. This was typically due to EKG abnormalities or high blood pressure. 2. Participants completed a practice run following consent to introduce them to equipment and procedures. Some participants choose not to continue following the practice run usually because of discomfort.
Participants by arm
| Arm | Count |
|---|---|
| Aim 1 - OSA Male - Sleep/Wake - Hypoxia/Sham We plan to study 10 OSA males. These males will be matched with 10 females with moderate obstructive sleep apnea (OSA), 10 healthy males and 10 healthy females. The males and the females will be matched based on age, race, sex and body mass index. The OSA and control participants will be exposed to intermittent hypoxia and sham intermittent hypoxia during wakefulness and sleep. | 11 |
| Aim 1 - OSA Female- Sleep/Wake - Hypoxia/Sham We plan to study 10 OSA females. These females will be matched with 10 males with moderate obstructive sleep apnea (OSA), 10 healthy males and 10 healthy females. The males and the females will be matched based on age, race, sex and body mass index. The OSA and control participants will be exposed to intermittent hypoxia and sham intermittent hypoxia during wakefulness and sleep. | 7 |
| Aim 1 - Healthy Males- Sleep/Wake - Hypoxia/Sham We plan to study 10 healthy males. These males will be matched with 10 OSA males and 10 OSA females with moderate obstructive sleep apnea (OSA), and 10 healthy males and 10 healthy females. The males and the females will be matched based on age, race, sex and body mass index. The OSA and control participants will be exposed to intermittent hypoxia and sham intermittent hypoxia during wakefulness and sleep. | 12 |
| Aim 1 - Healthy Females- Sleep/Wake - Hypoxia/Sham We plan to study 10 males and 10 females with moderate obstructive sleep apnea (OSA), and 10 healthy males and 10 healthy females. The males and the females will be matched based on age, race, sex and body mass index. The OSA and control participants will be exposed to intermittent hypoxia and sham intermittent hypoxia during wakefulness and sleep. | 10 |
| Aim 2 - OSA - Hypoxia - Antioxidant/Placebo We plan to study 10 male participants with moderate obstructive sleep apnea (OSA) and 10 male control participants matched for age, race and body mass index. The OSA and control participants will be exposed to intermittent hypoxia during wakefulness following administration of an antioxidant or a placebo cocktail that will be presented in a randomized fashion.
Antioxidant cocktail: 120 mg of Coenzyme Q10 (orally), 800 mg of Superoxide Dismutase (orally), 400 IU of Vitamin E (orally) before exposure to intermittent hypoxia. Two doses of 1 g of Vitamin C in 50 cc of saline IV (in the vein) before and after exposure to intermittent hypoxia. | 13 |
| Aim 2 - Healthy - Hypoxia - Antioxidant/Placebo We plan to study 10 male participants with moderate obstructive sleep apnea (OSA) and 10 male control participants matched for age, race and body mass index. The OSA and control participants will be exposed to intermittent hypoxia during wakefulness following administration of an antioxidant or a placebo cocktail that will be presented in a randomized fashion. | 10 |
| Total | 63 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Withdrawal by Subject | 3 | 0 |
Baseline characteristics
| Characteristic | Aim 1 - OSA Male - Sleep/Wake - Hypoxia/Sham | Total | Aim 2 - Healthy - Hypoxia - Antioxidant/Placebo | Aim 2 - OSA - Hypoxia - Antioxidant/Placebo | Aim 1 - Healthy Females- Sleep/Wake - Hypoxia/Sham | Aim 1 - Healthy Males- Sleep/Wake - Hypoxia/Sham | Aim 1 - OSA Female- Sleep/Wake - Hypoxia/Sham |
|---|---|---|---|---|---|---|---|
| Age, Customized | 24.8 years STANDARD_DEVIATION 3.1 | 26.6 years STANDARD_DEVIATION 5.4 | 29.1 years STANDARD_DEVIATION 5.1 | 31.2 years STANDARD_DEVIATION 6.2 | 24.8 years STANDARD_DEVIATION 4.1 | 25.2 years STANDARD_DEVIATION 4 | 26.6 years STANDARD_DEVIATION 5.9 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 1 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 11 Participants | 62 Participants | 9 Participants | 13 Participants | 10 Participants | 12 Participants | 7 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 5 Participants | 30 Participants | 6 Participants | 4 Participants | 5 Participants | 5 Participants | 5 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 6 Participants | 33 Participants | 4 Participants | 9 Participants | 5 Participants | 7 Participants | 2 Participants |
| Region of Enrollment United States | 11 participants | 63 participants | 10 participants | 13 participants | 10 participants | 12 participants | 7 participants |
| Sex: Female, Male Female | 0 Participants | 17 Participants | 0 Participants | 0 Participants | 10 Participants | 0 Participants | 7 Participants |
| Sex: Female, Male Male | 11 Participants | 46 Participants | 10 Participants | 13 Participants | 0 Participants | 12 Participants | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 0 / 40 | 0 / 23 |
| serious Total, serious adverse events | 0 / 40 | 0 / 23 |
Outcome results
Heart Rate Variability (Aim 2)
Heart rate variability (HRV) was measured before and after exposure to intermittent hypoxia following administration of a placebo or antioxidant cocktail. Heart rate variability refers to beat-to-beat alterations in heart rate. Under resting conditions, the electrocardiogram of healthy individuals reveals periodic variation in R-R intervals. To measure HRV, R-R interval data are presented in a graph, in which the y-axis plots the R-R intervals (ms2), and the x-axis the total number of beats. Spectral analysis of the graph transforms the signal from time to frequency on the x-axis (Hz), by representing the signal as a combination of sine and cosine waves, with different amplitudes and frequencies. The approach uses Fourier transforms. The heart rate spectrum contains a high frequency (0.15-0.4 Hz) component, which is synchronous with respiration and a low frequency (0.04 to 0.15 Hz) component that appears to be mediated by both the vagus and cardiac sympathetic nerves.
Time frame: Within the same experimental session
Population: Measurements were made before and after intermittent hypoxia following administration of a placebo or antioxidant cocktail. Please note that analysis of the heart rate variability measures for the healthy group have not been completed to date.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| OSA/HEALTHY - MALES/FEMALES - WAKE/SLEEP | Heart Rate Variability (Aim 2) | OSA before intermittent hypoxia placebo (HF) | 3766.1 ms2/Hz | Standard Error 1129.859 |
| OSA/HEALTHY - MALES/FEMALES - WAKE/SLEEP | Heart Rate Variability (Aim 2) | OSA after intermittent hypoxia placebo (HF) | 2944.9 ms2/Hz | Standard Error 935 |
| OSA/HEALTHY - MALES/FEMALES - WAKE/SLEEP | Heart Rate Variability (Aim 2) | OSA before intermittent hypoxia antioxidant (HF) | 3810.5 ms2/Hz | Standard Error 1712.2 |
| OSA/HEALTHY - MALES/FEMALES - WAKE/SLEEP | Heart Rate Variability (Aim 2) | OSA after intermittent hypoxia antioxidant (HF) | 2516.3 ms2/Hz | Standard Error 835.8 |
| OSA/HEALTHY - MALES/FEMALES - WAKE/SLEEP | Heart Rate Variability (Aim 2) | OSA before intermittent hypoxia placebo (LF) | 2737.7 ms2/Hz | Standard Error 573.1 |
| OSA/HEALTHY - MALES/FEMALES - WAKE/SLEEP | Heart Rate Variability (Aim 2) | OSA after intermittent hypoxia placebo (LF) | 2289.1 ms2/Hz | Standard Error 568.1 |
| OSA/HEALTHY - MALES/FEMALES - WAKE/SLEEP | Heart Rate Variability (Aim 2) | OSA before intermittent hypoxia antioxidant (LF) | 2761.6 ms2/Hz | Standard Error 629.1 |
| OSA/HEALTHY - MALES/FEMALES - WAKE/SLEEP | Heart Rate Variability (Aim 2) | OSA after intermittent hypoxia antioxidant (LF) | 1889.9 ms2/Hz | Standard Error 336.3 |
Ventilation (Aim 1)
Ventilation was measured before and after exposure to intermittent hypoxia in males and females. Ventilation was measured using a pneumotachograph, which is a flow measuring device.
Time frame: Within the same experimental session
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| OSA/HEALTHY - MALES/FEMALES - WAKE/SLEEP | Ventilation (Aim 1) | OSA male during wakefulness | 1.19 fraction of baseline | Standard Error 0.03 |
| OSA/HEALTHY - MALES/FEMALES - WAKE/SLEEP | Ventilation (Aim 1) | OSA male during sleep | 1.14 fraction of baseline | Standard Error 0.03 |
| OSA/HEALTHY - MALES/FEMALES - WAKE/SLEEP | Ventilation (Aim 1) | OSA female during wakefulness | 1.35 fraction of baseline | Standard Error 0.03 |
| OSA/HEALTHY - MALES/FEMALES - WAKE/SLEEP | Ventilation (Aim 1) | OSA female during sleep | 1.16 fraction of baseline | Standard Error 0.05 |
| OSA/HEALTHY - MALES/FEMALES - WAKE/SLEEP | Ventilation (Aim 1) | Healthy male during wakefulness | 1.19 fraction of baseline | Standard Error 0.03 |
| OSA/HEALTHY - MALES/FEMALES - WAKE/SLEEP | Ventilation (Aim 1) | Healthy male during sleep | 1.09 fraction of baseline | Standard Error 0.03 |
| OSA/HEALTHY - MALES/FEMALES - WAKE/SLEEP | Ventilation (Aim 1) | Healthy female during wakefulness | 1.26 fraction of baseline | Standard Error 0.06 |
| OSA/HEALTHY - MALES/FEMALES - WAKE/SLEEP | Ventilation (Aim 1) | Healthy female during sleep | 1.08 fraction of baseline | Standard Error 0.04 |